JP6267231B2 - カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール - Google Patents

カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール Download PDF

Info

Publication number
JP6267231B2
JP6267231B2 JP2015549756A JP2015549756A JP6267231B2 JP 6267231 B2 JP6267231 B2 JP 6267231B2 JP 2015549756 A JP2015549756 A JP 2015549756A JP 2015549756 A JP2015549756 A JP 2015549756A JP 6267231 B2 JP6267231 B2 JP 6267231B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocyclyl
carbocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015549756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507502A5 (OSRAM
JP2016507502A (ja
Inventor
アッペンダー・ベラパルチ
チェタン・パドマカル・ダルネ
ダームパル・エス・ドッド
アンソニー・ジェイ・サンポグナロ
マーク・ディ・ウィットマン
セルヴァクマル・クマラヴェル
ディバカル・ムリック
チャンドラセカル・レディ・アール
ペイイン・リウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016507502A publication Critical patent/JP2016507502A/ja
Publication of JP2016507502A5 publication Critical patent/JP2016507502A5/ja
Application granted granted Critical
Publication of JP6267231B2 publication Critical patent/JP6267231B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015549756A 2012-12-21 2013-12-20 カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール Expired - Fee Related JP6267231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740564P 2012-12-21 2012-12-21
US61/740,564 2012-12-21
PCT/US2013/076795 WO2014100533A1 (en) 2012-12-21 2013-12-20 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS

Publications (3)

Publication Number Publication Date
JP2016507502A JP2016507502A (ja) 2016-03-10
JP2016507502A5 JP2016507502A5 (OSRAM) 2017-01-12
JP6267231B2 true JP6267231B2 (ja) 2018-01-24

Family

ID=49943572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549756A Expired - Fee Related JP6267231B2 (ja) 2012-12-21 2013-12-20 カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール

Country Status (5)

Country Link
US (1) US9556179B2 (OSRAM)
EP (1) EP2935271B1 (OSRAM)
JP (1) JP6267231B2 (OSRAM)
CN (1) CN105073751B (OSRAM)
WO (1) WO2014100533A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935272B1 (en) 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
ES2770693T3 (es) * 2014-06-19 2020-07-02 Bristol Myers Squibb Co Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
US10696693B2 (en) 2014-11-21 2020-06-30 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as TGF-beta inhibitors
EP3265454B1 (en) * 2015-03-02 2020-02-26 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
JP6827948B2 (ja) 2015-03-23 2021-02-10 ザ ユニヴァーシティー オブ メルボルン 呼吸器疾患の治療
AU2016304182B2 (en) 2015-07-31 2020-08-27 Merck Patent Gmbh Bicyclic heterocyclic derivatives
CA3037222C (en) 2016-09-21 2024-02-13 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
EP3774795B1 (en) * 2018-03-29 2022-03-16 Masarykova Univerzita 4-(1h- imidazol- 5- yl) -1h-pyrrolo [2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors
EP3846818A1 (en) * 2018-09-09 2021-07-14 Qanatpharma AG Use of casein kinase 1 inhibitors for treating vascular diseases
EP3877383A4 (en) 2018-11-07 2022-09-21 The University of Melbourne COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
US11739078B2 (en) * 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
KR20230153407A (ko) 2021-02-24 2023-11-06 인실리코 메디신 아이피 리미티드 질환의 치료를 위한 유사체
WO2025231117A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof
WO2025231112A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008016131A1 (en) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US8703811B2 (en) 2008-05-07 2014-04-22 Genzyme Corporation Small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
HRP20140252T1 (hr) 2009-10-28 2014-04-25 Pfizer Inc. Derivati imidazola kao inhibitori kazeinske kinaze
EP2935272B1 (en) 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Also Published As

Publication number Publication date
EP2935271A1 (en) 2015-10-28
JP2016507502A (ja) 2016-03-10
CN105073751B (zh) 2018-11-30
US9556179B2 (en) 2017-01-31
WO2014100533A1 (en) 2014-06-26
CN105073751A (zh) 2015-11-18
EP2935271B1 (en) 2017-10-25
US20150344481A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP6494622B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
EP2350081B1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
EA029312B1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
AU2014351413B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
BR112020026337A2 (pt) Compostos tricíclicos
JP2023537586A (ja) Ｃｄｋ９阻害剤およびその使用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171221

R150 Certificate of patent or registration of utility model

Ref document number: 6267231

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees